Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended December 31, 2016; comparative periods ended December 31, 2015. The filing was dated February 13, 2017. Vistagen is a clinical-stage biotechnology company with no approved products and no recurring product revenue.
Business context and outlook
The company’s lead candidate, oral AV-101, was in Phase 2 development for major depressive disorder (MDD). The NIMH was conducting and fully funding a Phase 2a monotherapy study. Vistagen was preparing a roughly 280-patient Phase 2b adjunctive-treatment study. Its wholly owned VistaStem subsidiary pursued stem-cell-related drug discovery and regenerative medicine programs.
- Management expected the NIMH Phase 2a study to finish by the end of 2017, Phase 2b to begin by the end of the second quarter of 2017, and Phase 2b topline results by the end of 2018.
- In December 2016, Vistagen sublicensed certain cardiac stem-cell production technology to BlueRock Therapeutics. It recognized a $1.25 million upfront fee in the quarter and received the cash on January 5, 2017. Further milestone payments and royalties depend on future events and sales.
Financial performance and liquidity
| Metric | Three months ended Dec. 31, 2016 | Nine months ended Dec. 31, 2016 |
|---|---|---|
| Revenue | $1.25 million | $1.25 million |
| Research and development | $1.61 million | $4.04 million |
| General and administrative | $2.28 million | $4.91 million |
| Operating loss | $2.64 million | $7.70 million |
| Net loss | $2.64 million | $7.71 million |
| Net loss attributable to common stockholders | $2.88 million | $8.84 million |
| Basic and diluted loss per share | $0.34 | $1.23 |
- Revenue was entirely the one-time BlueRock sublicense fee; the filing reports no recurring revenue from AV-101 or other product candidates. Product gross margin is not applicable to this revenue mix.
- For the nine months, operating cash outflow was $5.97 million, investing cash outflow $9,900, and financing cash inflow $9.92 million. Cash increased $3.94 million to $4.37 million. Financing included approximately $9.5 million net proceeds from a May 2016 public offering.
- At December 31, 2016, current assets were $5.77 million and current liabilities $1.87 million, including a $1.25 million sublicense receivable. Total assets were $5.88 million, liabilities $3.29 million, and stockholders’ equity $2.59 million.
- Notes payable were $35,800, all current; capital lease obligations were $300. Accrued Series B preferred dividends were $1.34 million. The filing reports no off-balance-sheet arrangements.
- Management said available resources were expected to fund operations at least through the first half of 2017, including preparation for and launch of Phase 2b, but not completion of that study. The company filed a Form S-3 registration statement in January 2017 covering potential future sales of up to $100 million of securities; this was not committed financing.
Changes versus prior-year periods
- Quarterly revenue rose from zero to $1.25 million due to the sublicense fee. Quarterly R&D doubled to $1.61 million, chiefly reflecting AV-101 development and Phase 2b preparation; quarterly G&A increased to $2.28 million, including higher professional, investor-relations, and equity-compensation costs. Quarterly net loss widened to $2.64 million from $2.15 million.
- Nine-month R&D increased about 43% to $4.04 million, while G&A fell to $4.91 million from $6.51 million, primarily because prior-year stock-based compensation was unusually high. Operating expenses declined to $8.95 million from $9.35 million.
- Nine-month net loss improved to $7.71 million from $38.72 million. The prior-year result included a $26.70 million noncash loss on debt extinguishment and a $1.89 million warrant-liability expense, as well as higher interest expense. Thus, the large year-over-year reduction does not represent a comparable improvement in recurring operations.
- Operating cash use increased to $5.97 million from $3.50 million, despite the lower reported net loss. The period included the $1.25 million sublicense receivable, which was collected after quarter-end.
Risks, contingencies, and unusual items
- The company reported recurring losses, a $139.4 million accumulated deficit, and expected continuing losses and negative operating cash flows. It warned that failure to obtain timely, acceptable additional financing could require it to reduce or discontinue development activities and could threaten its ability to continue as a going concern.
- AV-101 remained subject to clinical, safety, manufacturing, regulatory, and patient-enrollment risks. Management stated that Phase 2b funding was not yet sufficient to complete the study and that future financing was not assured. Additional equity financing could dilute shareholders.
- The reported period included significant noncash compensation and warrant-modification expenses. In the nine months, the company recorded $573,900 of stock-based compensation and $427,500 of warrant-modification expense; professional-service providers were also compensated partly in shares.
- The company extended its headquarters lease through July 31, 2022. It reported no legal proceedings and no subsequent event requiring disclosure through February 10, 2017. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
- Key risks include reliance on AV-101, uncertain clinical outcomes, dependence on third-party clinical and manufacturing providers, limited patent protection for AV-101, competition, and potential dilution or limited trading liquidity.
Most important facts for investors to verify
- Whether the BlueRock upfront payment was collected as reported and whether any contingent milestones or royalties become payable.
- Whether Phase 2a completion, Phase 2b launch, and the projected study timelines were achieved, and what subsequent clinical results showed.
- Cash burn and financing runway after the January 2017 sublicense receipt, including whether additional funding was raised and on what terms.
- The full dilution potential from preferred stock, warrants, options, and any securities issued under the Form S-3.
- Whether AV-101’s clinical, regulatory, and intellectual-property prospects support the company’s stated development plans.